Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis
Introduction: Individuals with end-stage kidney disease (ESKD) maintained on hemodialysis (HD) carry a high risk of cardiac arrhythmias. This risk is heightened by episodic hyperkalemia. The purpose of the study was to investigate whether patiromer administered daily reduced episodes of hyperkalemia...
Saved in:
| Main Authors: | John P. Middleton, Shifeng Sun, Susan Murray, Clemontina A. Davenport, James P. Daubert |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924018771 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Case of Bradycardia Occured in the Setting of Hyperkalemia in a Patient in Ambulatory Hemodialysis Department
by: G. A. Ignatenko, et al.
Published: (2021-01-01) -
A Retrospective Study of Patiromer as Adjunct to Insulin Therapy for Acute Hyperkalemia in the Emergency Department
by: Goriacko P, et al.
Published: (2024-12-01) -
Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study
by: Zhao Xinju, et al.
Published: (2025-07-01) -
Severe respiratory acidosis contributing to refractory hyperkalemia: a case series of COVID-19 patients with renal failure
by: Nabadwip Pathak, et al.
Published: (2024-06-01) -
Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial
by: Mohamed Mamdouh Elsayed, et al.
Published: (2025-05-01)